a total of 30 patients responded to the questionnaire on long term oxygen therapy. Included subjects are patients who are currently using oxygen therapy or are expected to use oxygen in the near future. We also collected medical records of these patients.
68.6 years. Underlying disease were COPD(n = 15), bronchial asthma (n = 4), ILD(N = 4), bronchiectasis(n = 3), TB destroyed lung(n = 3), and others. In patients using home oxygen therapy, mean duration per day was 7.7 h. In 19 out of 25 patients, patients were reported to have improved symptoms and quality of life after using oxygen. The most uncomfortable aspects of using oxygen were as follows: noise(n = 14), restriction of ambulation(n = 11), cost(n = 6), dryness in the nose(n = 6). The reasons for avoiding use when recommended for oxygen were as follows: the eyes of others(n = 8), fear of permanent use(n = 5). A total of 10 out of 30 patients refused portable oxygen therapy. The reasons for avoiding use were as follows: the eyes of others(n = 14), heaviness when ambulation or moving(n = 13).
Conclusion:
We found that most patients with chronic lung diseases who used long term oxygen felt beneficial effects, but there were still obstacles that we have to overcome such as technical problems and too much consciousness of the eyes of others. In order to improve the patient's adherence to oxygen therapy, continuous monitoring and education on awareness about oxygen therapy and technical innovation are necessary. Background and Aims: Diabetes mellitus (DM) is a common comorbidity among patients with chronic obstructive pulmonary disease (COPD) and is probably associated with increased systemic inflammation and worse prognosis. Metformin, with its pleiotropic anti-inflammatory and antioxidant actions, may offer theoretical benefits in COPD patients with DM. Thus, this study aimed to investigate the effects of DM and metformin use on mortality in the clinical trajectory of COPD.
Methods:
We conducted a retrospective cohort study comprising patients with spirometry-confirmed COPD and an age of ≥40 years during the period 2008-2014. The primary outcome of interest was all-cause mortality. We evaluated the effect of DM on mortality through the clinical course of COPD and we also assessed the impact of metformin use on survival of the COPD population.
Results: Among 4231 COPD patients, 556 (13%) had comorbid DM and these patients had 1.62 times higher hazards of 2-year mortality than those without DM (95% confidence interval [CI], 1.15-2.28) after adjusting for age, gender, COPD stage, comorbidities and prior COPD hospitalization. Over a 2-year period, metformin users had a significantly lower risk of death (hazard ratio, 0.45; 95% CI, 0.23-0.88) compared to non-metformin users in patients with coexistent COPD and DM (Figure 1) . Moreover, metformin users had similar survival to COPD patients without DM.
Conclusion:
This study suggests that DM ties to an increased risk of death in COPD patients and the use of metformin seems to mitigate the hazard. Our findings support a pivotal role of metformin in the management of DM in COPD. Methods: Selected COPD patients for long-term follow-up since on June 2016. The subjects were required to fill out the related journal of the disease and wear a specific intelligent wristbands to recorded the daily activities and sleeping , Regular pulmonary function tracking, CAT, MMRC and six minute walk test were followed up.
Results: Until May 201 years, 46 subjects were temporarily met, with an average age of 65.96AE 6.09 years, GOLD group: I: 5 (11%), II: 20 (44.4%), III: 14 (31.1%), IV class: 4 (13.3%). After 37.11 AE 27.68 weeks, the daily activities and sleeping records of COPD patients were obtained for a total of 11948 days; The daily and mileage were positively correlated with FVC before and after bronchodilation test, FEV1 before and after bronchodilation test, FEV1/FVC after bronchodilation test, FEV1/ predicted value after bronchodilation test, MMEF after bronchodilation test, and total distance of 6 minutes walking test (r = 0.166~0.503, P = 0.000~0.044), showing a negative correlation with CAT table score and mMRC classification (r = −0.355~-0.401). There was no significant correlation between MMEF and FEV1/FVC after bronchodilation test. The total sleeping was positively correlated with FVC before and after bronchodilation test (r = 0.180, 0.166, P = 0.031, 0.047), deep sleeping and six minute walk distance, FVC before and after bronchodilation test, FEV1, FEV1/ predicted value before and after bronchodilation test, FEV1/FVC after bronchodilation test, MMEF significant before and after bronchodilation test (r = 0.3.10~0.167, P = 0.00~0.045), deep sleeping .
Conclusion: intelligent wristbands can track the steps and sleep of patients with COPD, which can be used to guide the tracking and management of patients.
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